Literature DB >> 11602999

FDG-PET in adrenocortical carcinoma.

A Becherer1, H Vierhapper, C Pötzi, G Karanikas, A Kurtaran, J Schmaljohann, A Staudenherz, R Dudczak, K Kletter.   

Abstract

Adrenal cortical carcinoma (ACC) is a rare malignant neoplasm with a poor prognosis. Radical surgery of the primary tumor and of local as well as of distant recurrence is the only effective treatment, and requires accurate and early localization of recurrent tumors. In this regard, we prospectively scanned 10 patients with ACC, 8 during follow-up and 2 at primary work-up. In all patients PET scans from the neck to the upper thighs were obtained 45 minutes after injection of 370 MBq [18F]FDG. Reading was done visually, with the investigator blinded to the results of other diagnostic modalities. All known sites of ACC lesions showed markedly increased FDG uptake. In 3 patients, previously unknown lesions were identified by PET in the lung (one lesion), the abdomen (3 lesions), and the skeleton (multiple), respectively. One false positive liver focus was shown by PET aside from the true positive lung metastases in the same patient. The sensitivity/specificity of PET based on different organs was 100/97%, that based on the number of PET-detected lesions (N = 23) was 100/95%. PET altered or influenced the tumor stage in 3/10 patients, modifying the subsequent therapeutic management in 2/10 patients. We conclude that FDG-PET is highly useful in ACC and should be included in the work-up for initial staging as well as for follow-up.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602999     DOI: 10.1089/108497801753131363

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  8 in total

1.  Giant adrenal pseudocyst harbouring adrenocortical cancer.

Authors:  Michael Wilkinson; Deirdre Mary Fanning; James Moloney; Hugh Flood
Journal:  BMJ Case Rep       Date:  2011-09-26

2.  Imaging of adrenocortical metastases with [11C]metomidate.

Authors:  Markus Mitterhauser; Georg Dobrozemsky; Georg Zettinig; Wolfgang Wadsak; Heinrich Vierhapper; Robert Dudczak; Kurt Kletter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-05-24       Impact factor: 9.236

3.  Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate.

Authors:  Georg Zettinig; Markus Mitterhauser; Wolfgang Wadsak; Alexander Becherer; Christian Pirich; Heinrich Vierhapper; Bruno Niederle; Robert Dudczak; Kurt Kletter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-10       Impact factor: 9.236

4.  Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using (18)F-FDG positron emission tomography.

Authors:  Rudolf A Werner; Matthias Kroiss; Masatoyo Nakajo; Dirk O Mügge; Stefanie Hahner; Martin Fassnacht; Andreas Schirbel; Christina Bluemel; Takahiro Higuchi; Laszló Papp; Norbert Zsótér; Andreas K Buck; Ralph A Bundschuh; Constantin Lapa
Journal:  Endocrine       Date:  2016-05-02       Impact factor: 3.633

Review 5.  Adrenal tumors: how to establish malignancy ?

Authors:  M Fassnacht; W Kenn; B Allolio
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

Review 6.  Molecular imaging of adrenal neoplasms.

Authors:  Clara C Chen; Jorge A Carrasquillo
Journal:  J Surg Oncol       Date:  2012-05-24       Impact factor: 2.885

7.  Childhood adrenocortical carcinoma: Case report and review.

Authors:  Abhay Gundgurthi; Sandeep Kharb; Manoj K Dutta; M K Garg; Abhisek Khare; M Joseph Jacob; Reena Bhardwaj
Journal:  Indian J Endocrinol Metab       Date:  2012-05

Review 8.  PET-CT and PET-MR in urological cancers other than prostate cancer: An update on state of the art.

Authors:  Abdul Razik; Chandan Jyoti Das; Sanjay Sharma
Journal:  Indian J Urol       Date:  2018 Jan-Mar
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.